#vaccine research

The research is vital because Epstein-Barr virus is linked to cancers, lupus, rheumatoid arthritis, multiple sclerosis and other conditions.

Vaccines designed to produce a strong T cell response may help protect against current and future SARS-CoV-2 variants.

Over the past decade, the field of mRNA therapeutics has advanced rapidly.

A vaccine designed to enhance T-cell activity could help CAR-T therapy work better against solid tumors.

CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.

The quick spread of the BA.2 subvariant is likely due to its greater infectiousness rather than its ability to evade the immune system.

NIAID is preparing for the possibility of future variants evading protection against currently available COVID-19 vaccines.

The benefits of achieving herd immunity thresholds have been less successful with respiratory viruses that continually mutate.

Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.

An NIH-sponsored study assessed boosters for adults fully vaccinated with any authorized or approved COVID-19 vaccine.

The success of the mRNA COVID-19 vaccines could help accelerate clinical research on vaccines to treat cancer.

The PreHevbrio vaccine produces higher antibody levels and offers faster protection.

The findings suggest boosters not only lengthen immunity but help broaden and strengthen the immune response.

An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.

The protein subunit vaccine provides 100% protection against moderate or severe disease, hospitalization and death.

The protein vaccine was 96% effective against the original SARS-CoV-2 coronavirus, but less so against new variants.